- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00227669
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether giving gemcitabine together with docetaxel is more effective than giving gemcitabine alone as second-line therapy in treating uterine or soft tissue leiomyosarcoma.
PURPOSE: This randomized phase II trial is studying gemcitabine and docetaxel to see how well they work compared to gemcitabine alone as second-line therapy in treating patients with metastatic or relapsed, unresectable uterine or soft tissue leiomyosarcoma.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- Compare the anti-tumor activity, in terms of objective response rate, in patients with metastatic or relapsed, unresectable uterine or soft tissue leiomyosarcoma treated with gemcitabine with vs without docetaxel as second-line therapy.
Secondary
- Compare the progression-free survival of patients treated with these regimens.
- Compare the response duration and overall survival of patients treated with these regimens.
- Compare the tolerability and dose intensity of these regimens in these patients.
- Determine biological markers with a predictive value for response to these regimens in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to location of leiomyosarcoma (uterine vs soft tissue). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemcitabine on days 1, 8, and 15. Treatment repeats every 4 weeks for 2-8 courses.
- Arm II: Patients receive gemcitabine on days 1 and 8 and docetaxel on day 8. Treatment repeats every 3 weeks for 2-8 courses.
PROJECTED ACCRUAL: A minimum of 80 patients (40 per stratum and treatment arm) will be accrued for this study.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Amiens, Francia, 80054
- Centre Hospitalier Universitaire D'Amiens
-
Angers, Francia, 49036
- Centre Paul Papin
-
Beauvais, Francia, 60021
- C.H.G. Beauvais
-
Bordeaux, Francia, 33076
- Institut Bergonie
-
Brest, Francia, 29609
- C.H.U. de Brest
-
Caen, Francia, 14076
- Centre Regional Francois Baclesse
-
Clermont-Ferrand, Francia, 63011
- Centre Jean Perrin
-
Colmar, Francia, 68024
- Hôpital Louis Pasteur
-
Dijon, Francia, 21079
- Centre de Lutte Contre le Cancer Georges-Francois Leclerc
-
Lille, Francia, 59020
- Centre Oscar Lambret
-
Lyon, Francia, 69437
- Hopital Edouard Herriot - Lyon
-
Lyon, Francia, 69373
- Centre Léon Bérard
-
Marseille, Francia, 13385
- CHU de la Timone
-
Marseille, Francia, 13915
- CHU Nord
-
Montpellier, Francia, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Nantes, Francia, 44093
- CHR Hotel Dieu
-
Nantes-Saint Herblain, Francia, 44805
- Centre Regional Rene Gauducheau
-
Nice, Francia, 06189
- Centre Antoine Lacassagne
-
Orleans, Francia, 45067
- CHR D'Orleans - Hopital de la Source
-
Paris, Francia, 75018
- Hopital Bichat - Claude Bernard
-
Paris, Francia, 75674
- Hôpital Cochin
-
Paris, Francia, 75475
- Hôpital Saint-Louis
-
Paris, Francia, 75248
- Institut Curie Hopital
-
Poitiers, Francia, 86021
- CHU Poitiers
-
Rennes, Francia, 35042
- Centre Eugene Marquis
-
Rouen, Francia, 76038
- Centre Henri Becquerel
-
Rouen, Francia, 76031
- Hôpital Charles Nicolle
-
Saint Cloud, Francia, 92211
- Centre René Huguenin
-
Saint Priest en Jarez, Francia, 42270
- Institut de Cancérologie de la Loire
-
Toulouse, Francia, 31052
- Institut Claudius Regaud
-
Tours, Francia, 37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
Villejuif, Francia, F-94805
- Institut Gustave Roussy
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically confirmed uterine or soft tissue leiomyosarcoma, meeting ≥ 1 of the following criteria:
- Metastatic disease
- Relapsed and unresectable disease
Prior treatment with a first-line anthracycline-based chemotherapy regimen required
- Relapsed disease > 1 year after adjuvant chemotherapy is considered untreated disease
- If relapsed disease occurs < 1 year after adjuvant therapy, then adjuvant therapy is considered a first-line treatment
At least 1 measurable lesion, defined as the following:
- At least 1 target lesion must be located in a non-irradiated area
- Obvious disease progression within the past 6 weeks
No other uterine sarcomas, including any of the following:
- Carcinosarcoma
- Endometrial stroma sarcoma
- Other soft tissue sarcoma
- No symptomatic or known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- WHO 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- No specific hepatic contraindication to study treatment
- Hepatitis B core and hepatitis B surface antigen negative
Renal
- Creatinine < 1.5 times ULN
- No specific renal contraindication to study treatment
Cardiovascular
- No specific cardiac contraindication to study treatment
Immunologic
- HIV negative
- No specific allergic contraindication to study treatment
- No active infection
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No other serious underlying pathology that would preclude study treatment
- No other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix
- No neurotoxicity > grade 2
- No psychological, sociological, or geographical condition that would preclude study compliance or follow-up schedule
- No prior or concurrent psychiatric illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 4 weeks since prior immunotherapy
- No prior allogeneic graft or autologous graft
Chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior chemotherapy
- No prior gemcitabine and/or taxane (i.e., docetaxel or paclitaxel)
Endocrine therapy
- More than 4 weeks since prior hormonal therapy
Radiotherapy
- See Disease Characteristics
- More than 4 weeks since prior radiotherapy
- No prior radiotherapy to the only evaluable lesion
Surgery
- Not specified
Other
- No concurrent participation in another clinical trial using an experimental agent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Arm I: Gemcitabine
Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22. 1 cycle = 28 days. Treatment duration: 8 months |
|
|
Experimental: Arm II: Gemcitabine + Docetaxel
Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8. 1 cycle = 21 days. Treatment duration: 6 months |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Anti-tumoral activity (objective response rate)
Periodo de tiempo: 6 months
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Sobrevivencia promedio
Periodo de tiempo: 3 años
|
3 años
|
|
Supervivencia libre de progresión
Periodo de tiempo: 6 meses
|
6 meses
|
|
Duración de la respuesta
Periodo de tiempo: 3 años
|
3 años
|
|
Tolerability
Periodo de tiempo: 3 years
|
3 years
|
|
Dose intensity
Periodo de tiempo: 3 years
|
3 years
|
|
Biological markers
Periodo de tiempo: 3 years
|
3 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Florence Duffaud, MD, CHU de la Timone
Publicaciones y enlaces útiles
Publicaciones Generales
- Duffaud F, Bui BN, Penel N, et al.: A FNCLCC French Sarcoma Group--GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). [Abstract] J Clin Oncol 26 (Suppl 15): A-10511, 2008.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias De Tejidos Conectivos Y Blandos
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias De Tejido Muscular
- Sarcoma
- Leiomiosarcoma
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Gemcitabina
- Docetaxel
Otros números de identificación del estudio
- CDR0000443572
- FRE-FNCLCC-SARCOME-07/0410
- EU-20518
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .